Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

The changing context of hepatitis D
Mario Rizzetto, Saeed Hamid, F. Negro
Journal of Hepatology (2021) Vol. 74, Iss. 5, pp. 1200-1211
Open Access | Times Cited: 125

Showing 1-25 of 125 citing articles:

Hepatitis D virus in 2021: virology, immunology and new treatment approaches for a difficult-to-treat disease
Stephan Urban, Christoph Neumann‐Haefelin, Pietro Lampertico
Gut (2021) Vol. 70, Iss. 9, pp. 1782-1794
Open Access | Times Cited: 171
The EASL–Lancet Liver Commission: protecting the next generation of Europeans against liver disease complications and premature mortality
Tom H. Karlsen, Nick Sheron, Shira Zelber‐Sagi, et al.
The Lancet (2021) Vol. 399, Iss. 10319, pp. 61-116
Open Access | Times Cited: 170
EASL Clinical Practice Guidelines on hepatitis delta virus
Maurizia Rossana Brunetto, G. Ricco, Francesco Negro, et al.
Journal of Hepatology (2023) Vol. 79, Iss. 2, pp. 433-460
Open Access | Times Cited: 129
A Phase 3, Randomized Trial of Bulevirtide in Chronic Hepatitis D
Heiner Wedemeyer, Soo Aleman, Maurizia Rossana Brunetto, et al.
New England Journal of Medicine (2023) Vol. 389, Iss. 1, pp. 22-32
Open Access | Times Cited: 119
Hepatitis D Virus Infection
Tarik Asselah, Mario Rizzetto
New England Journal of Medicine (2023) Vol. 389, Iss. 1, pp. 58-70
Closed Access | Times Cited: 51
Treating hepatitis D with bulevirtide – Real-world experience from 114 patients
Christopher Dietz-Fricke, Frank Tacke, Caroline Zöllner, et al.
JHEP Reports (2023) Vol. 5, Iss. 4, pp. 100686-100686
Open Access | Times Cited: 43
Implementation of anti-HDV reflex testing among HBsAg-positive individuals increases testing for hepatitis D
Adriana Palom, Ariadna Rando‐Segura, Judit Vico, et al.
JHEP Reports (2022) Vol. 4, Iss. 10, pp. 100547-100547
Open Access | Times Cited: 63
Safety and effectiveness of up to 3 years’ bulevirtide monotherapy in patients with HDV-related cirrhosis
Alessandro Loglio, Péter Ferenci, Sara Uceda Renteria, et al.
Journal of Hepatology (2021) Vol. 76, Iss. 2, pp. 464-469
Closed Access | Times Cited: 56
Bulevirtide monotherapy for 48 weeks in patients with HDV-related compensated cirrhosis and clinically significant portal hypertension
Elisabetta Degasperi, Maria Paola Anolli, Sara Uceda Renteria, et al.
Journal of Hepatology (2022) Vol. 77, Iss. 6, pp. 1525-1531
Closed Access | Times Cited: 50
Hepatitis D virus-induced interferon response and administered interferons control cell division-mediated virus spread
Zhenfeng Zhang, Yi Ni, Florian A. Lempp, et al.
Journal of Hepatology (2022) Vol. 77, Iss. 4, pp. 957-966
Closed Access | Times Cited: 48
Hepatitis D double reflex testing of all hepatitis B carriers in low-HBV- and high-HBV/HDV-prevalence countries
Homie Razavi, Marı́a Buti, Norah A. Terrault, et al.
Journal of Hepatology (2023) Vol. 79, Iss. 2, pp. 576-580
Open Access | Times Cited: 36
Bulevirtide monotherapy in patients with chronic HDV: Efficacy and safety results through week 96 from a phase III randomized trial
Heiner Wedemeyer, Soo Aleman, Maurizia Rossana Brunetto, et al.
Journal of Hepatology (2024) Vol. 81, Iss. 4, pp. 621-629
Open Access | Times Cited: 12
Hepatitis Delta Virus and Hepatocellular Carcinoma
Daniele Lombardo, Maria Stella Franzè, Giuseppe Caminiti, et al.
Pathogens (2024) Vol. 13, Iss. 5, pp. 362-362
Open Access | Times Cited: 8
Low coverage of hepatitis D virus testing in individuals with hepatitis B virus and HIV, the Netherlands, 2000 to 2022
Anders Boyd, Colette Smit, Annemiek A. van der Eijk, et al.
Eurosurveillance (2025) Vol. 30, Iss. 7
Open Access | Times Cited: 1
Hepatitis D Virus and Hepatocellular Carcinoma
Patrizia Farci, Grazia Anna Niro, Fausto Zamboni, et al.
Viruses (2021) Vol. 13, Iss. 5, pp. 830-830
Open Access | Times Cited: 43
Viral hepatitis: Milestones, unresolved issues, and future goals
Pietro Torre, Andrea Aglitti, Mario Masarone, et al.
World Journal of Gastroenterology (2021) Vol. 27, Iss. 28, pp. 4603-4638
Open Access | Times Cited: 42
Update on the management and treatment of viral hepatitis
Patrícia Holanda Almeida, Celso Eduardo Lourenço Matielo, Lílian Amorim Curvêlo, et al.
World Journal of Gastroenterology (2021) Vol. 27, Iss. 23, pp. 3249-3261
Open Access | Times Cited: 41
A Review of HDV Infection
Gian Paolo Caviglia, Alessia Ciancio, Mario Rizzetto
Viruses (2022) Vol. 14, Iss. 8, pp. 1749-1749
Open Access | Times Cited: 33
CRISPR/Cas13a-Assisted accurate and portable hepatitis D virus RNA detection
Yuan Tian, Zihao Fan, Xiangying Zhang, et al.
Emerging Microbes & Infections (2023) Vol. 12, Iss. 2
Open Access | Times Cited: 18
Nanopore efficiently identifies hepatitis D virus antigens in vitro assay
Lingyu Zhao, Yingying Deng, Yunjiao Wang, et al.
Materials Today Physics (2024) Vol. 46, pp. 101479-101479
Closed Access | Times Cited: 7
Clinical long-term outcome of hepatitis D compared to hepatitis B monoinfection
A. Wranke, Benjamin Heidrich, Katja Deterding, et al.
Hepatology International (2023) Vol. 17, Iss. 6, pp. 1359-1367
Open Access | Times Cited: 15
Hepatitis D virus infection: Pathophysiology, epidemiology and treatment. Report from the first international delta cure meeting 2022
Pietro Lampertico, Elisabetta Degasperi, Lisa Sandmann, et al.
JHEP Reports (2023) Vol. 5, Iss. 9, pp. 100818-100818
Open Access | Times Cited: 14
Exploring Predictive Factors for Bulevirtide Treatment Response in Hepatitis Delta-Positive Patients
Verdiana Zulian, Leonidas Salichos, Chiara Taibi, et al.
Biomedicines (2025) Vol. 13, Iss. 2, pp. 280-280
Open Access
Severe Liver‐Related Outcomes in Patients With Hepatitis Delta: Results From a Multi‐Ethnic Multicenter Long‐Term Follow‐Up Study
Arno Furquim d’Almeida, Erwin Ho, Liesbeth Govaerts, et al.
Journal of Viral Hepatitis (2025) Vol. 32, Iss. 2, pp. 1-15
Open Access
Liver diseases: epidemiology, causes, trends and predictions
Can Gan, Yuan Yuan, Haiyuan Shen, et al.
Signal Transduction and Targeted Therapy (2025) Vol. 10, Iss. 1
Open Access
Page 1 - Next Page

Scroll to top